|Application ||WB, FC, E|
|Calculated MW||65273 Da|
|Antigen Region||21-48 aa|
|Other Names||Acyl-coenzyme A synthetase ACSM1, mitochondrial, Acyl-CoA synthetase medium-chain family member 1, Butyrate--CoA ligase 1, Butyryl-coenzyme A synthetase 1, Lipoate-activating enzyme, Middle-chain acyl-CoA synthetase 1, ACSM1, BUCS1, LAE, MACS1|
|Target/Specificity||This ACSM1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 21-48 amino acids from the N-terminal region of human ACSM1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ACSM1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||BUCS1, LAE, MACS1|
|Function||Has medium-chain fatty acid:CoA ligase activity with broad substrate specificity (in vitro). Acts on acids from C(4) to C(11) and on the corresponding 3-hydroxy- and 2,3- or 3,4- unsaturated acids (in vitro). Functions as GTP-dependent lipoate- activating enzyme that generates the substrate for lipoyltransferase (By similarity).|
|Cellular Location||Mitochondrion matrix.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ACSM1 has medium-chain fatty acid:CoA ligase activity with broad substrate specificity (in vitro). This protein acts on acids from C(4) to C(11) and on the corresponding 3-hydroxy-and 2,3-or 3,4-unsaturated acids (in vitro). This protein functions as GTP-dependent lipoate-activating enzyme that generates the substrate for lipoyltransferase
Celis,J.E., et.al., Mol. Cell Proteomics 7 (10), 1795-1809 (2008)
Sullivan,P.F., et.al., Mol. Psychiatry 13 (6), 570-584 (2008)
Haketa,A., et.al., J. Hypertens. 22 (10), 1903-1907 (2004)
If you have any additional inquiries please email technical services at email@example.com.